or Try an Advanced Search...

    Hepatocellular Carcinoma Stocks List

    Symbol Grade Name % Change
    ABUS B Arbutus Biopharma Corporation 0.96
    CANF C Can-Fite Biopharma Ltd Sponsored ADR (Israel) 0.83
    SNTI D Senti Biosciences, Inc. -16.67
    RGLS D Regulus Therapeutics Inc. 2.27
    BCAB F BioAtla, Inc. 8.33
    TLSI F TriSalus Life Sciences, Inc. 9.49
    TCON F TRACON Pharmaceuticals, Inc. -24.12
    BFRG F Bullfrog AI Holdings, Inc -1.20
    View As Page of Charts
    Related Industries: Biotechnology Health Information Services Medical Devices
    Related Stock Lists: Biopharmaceutical Cancer Carcinoma Medicine Biotechnology Blastoma Cancer Immunotherapy Colorectal Cancer Disease Drugs Glioblastoma Renal Cell Carcinoma Targeted Therapy Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Age Related Macular Degeneration Alcohol Alnylam Pharmaceuticals Amyloid Amyloidosis

    Related ETFs - A few ETFs which own one or more of the above listed Hepatocellular Carcinoma stocks.

    Symbol Grade Name Weight
    GERM D ETFMG Treatments Testing and Advancements ETF 1.38
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 0.87
    FORH D Formidable ETF 0.68
    BTEC C Principal Healthcare Innovators Index ETF 0.18
    IWC C iShares Microcap ETF 0.12
    View all Hepatocellular Carcinoma ETFs...
    Compare ETFs
    Compare BTEC to IWC Compare FORH to IWC Compare GERM to BBC

        Hepatocellular Carcinoma Stocks Recent News

        Date Stock Title
        Jul 3 BCAB Insider Traders Lose US$67k As BioAtla Drops
        Jul 2 TCON Tracon mulls strategic options after sarcoma drug fails Phase II trial
        Jul 1 TLSI TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
        Jul 1 SNTI Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?
        Jul 1 TCON TRACON ends development of envafolimab, exploring strategic options
        Jul 1 TCON TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
        Jul 1 SNTI Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
        Jul 1 CANF Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
        Jun 28 CANF Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
        Jun 27 BCAB BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
        Related Industries: Biotechnology Health Information Services Medical Devices
        Related Stock Lists: Biopharmaceutical Cancer Carcinoma Medicine Biotechnology Blastoma Cancer Immunotherapy Colorectal Cancer Disease Drugs Glioblastoma Renal Cell Carcinoma Targeted Therapy Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Age Related Macular Degeneration Alcohol Alnylam Pharmaceuticals Amyloid Amyloidosis
        Hepatocellular Carcinoma

        Hepatocellular carcinoma (HCC) is a type of cancer that starts in the cells of the liver. It is the most common type of primary liver cancer and is one of the most common cancers worldwide. HCC is usually caused by chronic infection with the hepatitis B or C virus, or by cirrhosis due to alcohol abuse or other causes. Symptoms of HCC may include abdominal pain, jaundice, weight loss, and a feeling of fullness in the abdomen. Treatment options may include surgery, chemotherapy, radiation therapy, and targeted therapy.

        Browse All Tags